Vertex Pharmaceuticals price target raised to $407 from $402 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $407 from $402 and keeps a Sector Perform rating on the shares.
Vertex Pharmaceuticals price target raised to $467 from $435 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...